Rapid test to assess the escape of SARS-CoV-2 variants of concern.
Sci Adv
; 7(49): eabl7682, 2021 Dec 03.
Article
in English
| MEDLINE | ID: covidwho-1550871
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies (nAbs) capable of blocking interactions between the angiotensin-converting enzyme 2 receptor and the spike protein of wild-type (WT) SARS-CoV-2 and three other variants B.1.1.7, B.1.351, and P.1. Using CoVariant-SCAN, we assessed neutralization/blocking of monoclonal antibodies and plasma from COVID-19positive and vaccinated individuals. For several monoclonal antibodies and most plasma samples, neutralization against B.1.351 and P.1 variants is diminished relative to WT, while B.1.1.7 is largely cross-neutralized. We also showed that we can rapidly adapt the platform to detect nAbs against an additional variantB.1.617.2 (Delta)without reengineering or reoptimizing the assay. Results using CoVariant-SCAN are consistent with live virus neutralization assays and demonstrate that this easy-to-deploy test could be used to rapidly assess nAb response against multiple SARS-CoV-2 variants.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Randomized controlled trials
Topics:
Vaccines
/
Variants
Language:
English
Journal:
Sci Adv
Year:
2021
Document Type:
Article
Affiliation country:
Sciadv.abl7682
Similar
MEDLINE
...
LILACS
LIS